DESTINY-PanTumor02
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
- NCT04482309 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built an HCP commentary report on DESTINY-PanTumor02 (trastuzumab deruxtecan in HER2-expressing solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 40 newest of 222 indexed sources (Apr 2025 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether HER2 testing variability changes treatment eligibility or expected benefit
- How HER2 expression level should guide treatment selection
- Whether the ovarian cancer evidence is sufficient to guide treatment decisions
- How interstitial lung disease risk should influence treatment and retreatment decisions
Also discussed: first-line development.
Indexed commentary on DESTINY-PanTumor02 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 81 | |
| YouTube | 70 | |
| Podcasts | 69 | |
| Bluesky threads | 1 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer; Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
- Interventions
- Trastuzumab deruxtecan
- Arms
- Part 1 Cohort 1 · Experimental
- Part 1 Cohort 2 · Experimental
- Part 1 Cohort 3 · Experimental
- Part 1 Cohort 4 · Experimental
- Part 1 Cohort 5 · Experimental
- Part 1 Cohort 6 · Experimental
- Part 1 Cohort 7 · Experimental
- Part 2 Cohort A · Experimental
- Part 2 Cohort B · Experimental
- Part 2 Cohort C · Experimental
- Part 2 Cohort D · Experimental
- Part 2 Cohort E · Experimental
- Enrollment
- 477
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- AstraZeneca with Daiichi Sankyo Co., Ltd.
- Start
- Aug 18, 2020
- Primary completion
- Mar 23, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04482309 · updated Jul 10, 2026
Publications
linked from the registry- Lee JY, Oaknin A, Manso L, Gonzalez-Martin A, Lugowska I, Lorusso D, Banerjee S, Liao JB, Lu CH, Prasongsook N, Melichar B, Anoka C, Jung L, Michelini F, Puvvada S, Meric-Bernstam F, Makker V. Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses. J Gynecol Oncol. 2026 May;37(3):e65. doi: 10.3802/jgo.2026.37.e65. Epub 2026 May 6. PubMed 42135959
- Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, Gonzalez-Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Puvvada S, Smith A, Meric-Bernstam F. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Adv Ther. 2024 Nov;41(11):4125-4139. doi: 10.1007/s12325-024-02975-x. Epub 2024 Sep 11. PubMed 39261417
- Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonzalez-Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23. PubMed 37870536